PACIRA BIOSCIENCES, INC. Equity Securities, FV-NI, Unrealized Gain
PACIRA BIOSCIENCES, INC. (PCRX) reported Equity Securities, FV-NI, Unrealized Gain of $2.80 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-30.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2020-10-30
- PACIRA BIOSCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-09-30 was $2.80M.
- PACIRA BIOSCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-06-30 was $4.00M.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 9 month |
|---|---|---|---|
| 2020-09-30 | $2.80M 10-Q · filed 2020-10-30 | $6.80M derived: sum of 2 quarters · filed 2020-10-30 | $2.80M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $4.00M 10-Q · filed 2020-08-06 | $100.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |